Therefore, strategies aiming to inhibit BCR::ABL1 signaling despite its mutations are of increased importance for the functional cure of CML (Loscocco et al., 2019). The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.